← Back to Search

Other

Rasagiline for Depression (MOCP Trial)

N/A

Waitlist Available

Led By Jeffrey H Meyer, MD, PhD

Research Sponsored by Centre for Addiction and Mental Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

MOCP Trial Summary

This trial is studying how well a PET scan can show how well a depression medication is working by looking at how much of the medication is present in the brain.

Eligible Conditions

Depression
Major Depressive Disorder

MOCP Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

MAO-B occupancy of rasagiline at standard treating dose

Bloom Syndrome

Secondary outcome measures

Rasagiline effect on MAO-B distribution volume (VT) and cognition in MDE post COVID-19

Rasagiline effect on MAO-B distribution volume (VT) in the prefrontal cortex

MOCP Trial Design

3Treatment groups

Experimental Treatment

Group I: TranylcypromineExperimental Treatment1 Intervention

Assessment of regional MAO-B distribution volume before and after tranylcypromine at 30 to 60 mg daily.

Group II: RasagilineExperimental Treatment1 Intervention

Assessment of regional MAO-B distribution volume before and after rasagiline at 1.0 mg daily.

Group III: DuloxetineExperimental Treatment1 Intervention

Assessment of MAO-B distribution volume in the prefrontal cortex before and after duloxetine at 60 mg daily.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthLead Sponsor

354 Previous Clinical Trials

81,070 Total Patients Enrolled

85 Trials studying Depression

19,127 Patients Enrolled for Depression

Jeffrey H Meyer, MD, PhDPrincipal InvestigatorCAMH

3 Previous Clinical Trials

130 Total Patients Enrolled

2 Trials studying Depression

125 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants currently being recruited to take part in this trial?

"True. According to the information posted on clinicaltrials.gov, this medical study has been ongoing since April 15th 2021 and is still recruiting as of March 31st 2022. 30 participants are needed from a single medical centre."

Answered by AI

Is this trial taking in participants beyond the age of fifty?

"To qualify for this trial, participants must be aged between 18 and 80. According to the data available, there are 107 trials catered towards people younger than 18 years old and 604 studies devoted to patients above 65."

Answered by AI

What is the current participation level of this clinical experiment?

"Affirmative. Clinicaltrials.gov indicates that this study, which was created on April 15th 2021, is currently recruiting participants. The trial needs to enroll around 30 people from one site in total."

Answered by AI

How might I participate in this experiment?

"Qualified candidates for this clinical trial ought to suffer from major depressive disorder (MDD) and must be between the ages of 18-80. The total number of enrollees needed is 30."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

MAO-B Occupancy in Depressed Patients

2021. "MAO-B Occupancy in Depressed Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04841798.